Premium
Clearing up misunderstandings around core outcomes for atopic dermatitis
Author(s) -
Williams H.C.,
Apfelbacher C.,
Chalmers J.R.,
Schmitt J.,
Simpson E.L.,
Spuls P.I.,
Thomas K.S.
Publication year - 2015
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.13787
Subject(s) - atopic dermatitis , medicine , outcome (game theory) , clinical trial , alternative medicine , dermatology , family medicine , pathology , mathematics , mathematical economics
We thank Professor Taieb for his comments on the report of the Third International Consensus Meeting to Harmonise Core Outcome Measures for Atopic Eczema/Dermatitis Clinical Trials (HOME III) in the December 2014 issue of the BJD (1). He promulgates a number of misconceptions about our work which we wish to respond to. First, he suggests that the Outcome Measures in Rheumatology (OMERACT) filter "truth, discrimination and feasibility" might not be applicable to outcome measurement instruments for atopic dermatitis (AD) (2). This article is protected by copyright. All rights reserve